Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
INTERVIEW
Alzheimer’s Treatment at Crossroads? Top Expert on AD Research, Aducanumab and Its Implications - 1
Biogen’s closely watched Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first disease-modifying therapy and a definite game changer in the arena. How big is the potential target population in Japan…
To read the full story
Related Article
- With Aducanumab in Mind, Outgoing Chuikyo Payer Rep Floats Rule to Reward Cost Cuts for Pricey Meds
March 18, 2021
- From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
February 8, 2021
- Potential Reimbursement Challenges of Aducanumab Could Usher in Health Insurance Overhaul in Japan
January 8, 2021
INTERVIEW
- From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
February 8, 2021
- Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
February 10, 2020
- “Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician
January 28, 2020
- Causes of NDMA Contamination Scandal Still under Investigation: NIHS Division of Drugs
January 27, 2020
- Pharma Industry Watered Down Original Proposals for Pricing Overhaul, Corrections Necessary: Kenporen Director
September 12, 2019
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…